Hepatitis B Virus (HBV) Therapeutics – China Drug Forecast and Market Analysis to 2024
Summary
Chronic hepatitis B virus (HBV) infection is a serious chronic liver disease caused by the failure of viral clearance following acute HBV infection. Despite the availability of effective prophylactic vaccines, the disease remains a serious global health concern, with estimated over 350 million people worldwide currently living with this condition. In addition, patients with chronic hepatitis B are at a high risk of developing life-threatening complications including liver cirrhosis and hepatocellular carcinoma (HCC). In 2010, an estimated 786,000 HBV-related deaths occurred worldwide.
Available treatment for chronic hepatitis B focuses on viral suppression, and include oral nucleos(t)ide analogues (NAs) and pegylated interferon (PEG-IFN). The two therapy classes have distinctive strengths and weaknesses. Nevertheless, most patients are using long-term NA treatment, and suffer from issues such as high accumulated treatment cost and low compliance.
In 2014, the Chinese chronic hepatitis B therapeutic market was the largest among the 8MM in terms of total sales. Generic erosion of key brands occurred in China earlier than in the rest of the 8MM, with Baraclude, Hepsera, and Epivir-HBV having faced generic competition for some years. As a consequence, GlobalData estimates that over 30% of the total therapeutics sales in this market arose from generic sales.
*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.
Scope
– Overview of HBV including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
– Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.
– Sales forecast for the top drugs in China from 2014-2024.
– Analysis of the impact of key events as well the drivers and restraints affecting China HBV market.
Reasons to buy
– Understand and capitalize by identifying products that are most likely to ensure a robust return
– Stay ahead of the competition by understanding the changing competitive landscape for HBV.
– Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
– Make more informed business decisions from insightful and in-depth analysis of drug performance
– Obtain sales forecast for drugs from 2014-2024 in China.
“1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Overview
3.2 Etiology and Pathophysiology
3.2.1 Etiology
3.2.2 Pathophysiology
3.3 Symptoms
3.4 Prognosis
3.4.1 Phases of Chronic HBV Infection
3.4.2 Complications of Chronic Hepatitis B
3.5 Quality of Life
4 Disease Management
4.1 Diagnosis and Treatment Overview
4.1.1 Diagnosis
4.1.2 Treatment Guidelines and Leading Prescribed Drugs
4.1.3 Clinical Practice
4.2 China
4.2.1 Screening and Diagnosis
4.2.2 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 Product Profiles – Major Brands
5.2.1 Baraclude (entecavir)
5.2.2 Viread (tenofovir disoproxil fumarate)
5.2.3 Pegasys (peginterferon alfa-2a)
5.2.4 Hepsera (adefovir dipivoxil)
5.2.5 Tyzeka (telbivudine)
5.3 Other Therapeutics
5.3.1 Conventional and Pegylated Interferon alfa
5.3.2 Nucleos(t)ide Analogs
6 Unmet Need and Opportunity
6.1 Overview
6.2 Improvements in Long-Term Clinical Outcomes
6.2.1 Unmet Need
6.2.2 Gap Analysis
6.2.3 Opportunity
6.3 Enhanced Public Awareness and Screening Initiatives to Boost Diagnosis Rates
6.3.1 Unmet Need
6.3.2 Gap Analysis
6.3.3 Opportunity
6.4 Increased Access to Treatment
6.4.1 Unmet Need
6.4.2 Gap Analysis
6.4.3 Opportunity
6.5 Drugs That Effectively Target and Suppress HBV cccDNA
6.5.1 Unmet Need
6.5.2 Gap Analysis
6.5.3 Opportunity
6.6 Safe and Efficacious Therapies for Difficult-to-Treat Patients
6.6.1 Unmet Need
6.6.2 Gap Analysis
6.6.3 Opportunity
6.7 Overcome Unique Barriers Posed by China鈥檚 Healthcare System
6.7.1 Unmet Need
6.7.2 Gap Analysis
6.7.3 Opportunity
7 Pipeline Assessment
7.1 Overview
7.2 Clinical Trial Mapping
7.2.1 Clinical Trials by Phase and Status, Therapy Class, and Location
7.3 Promising Drugs in Clinical Development
7.3.1 Tenofovir Alafenamide Fumarate
7.3.2 ARC-520
7.3.3 GS-9620
7.3.4 GS-4774
7.4 Other Drugs in Development
7.4.1 ABX-203
7.4.2 REP 2139-Ca
7.4.3 Besifovir
7.4.4 Hepabulin
7.4.5 Myrcludex-B
7.4.6 Agents in Early Stages of Development
8 Market Outlook
8.1 China
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Total Prevalent Cases of Chronic Hepatitis B
9.4.2 Diagnosed Chronic Hepatitis B Patients
9.4.3 Percent Drug-Treated Chronic Hepatitis B Patients
9.4.4 Drugs Included in Each Therapeutic Class
9.4.5 Launch and Patent Expiry Dates
9.4.6 General Pricing Assumptions
9.4.7 Individual Drug Assumptions
9.4.8 Generic Erosion
9.4.9 Pricing of Pipeline Agents
9.5 Primary Research – KOLs Interviewed for this Report
9.6 Primary Research – Prescriber Survey
9.7 About the Authors
9.7.1 Analyst
9.7.2 Therapy Area Director
9.7.3 Epidemiologists
9.7.4 Global Director of Therapy Analysis and Epidemiology
9.7.5 Global Head of Healthcare
9.8 About GlobalData
9.9 Disclaimer”
